Genprex, Inc. (GNPX) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Genprex, Inc. is a clinical-stage gene therapy company developing treatments for oncology (Non-Small Cell Lung Cancer and Small Cell Lung Cancer) and diabetes. The company operates as a single segment and is currently focused on advancing its lead oncology candidate, REQORSA, through Phase 2 clinical trials while continuing preclinical development for its diabetes program.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,964,601) | $(5,968,869) |
| Net Loss Per Share (Basic & Diluted) | $(0.26) | $(3.86) |
| Operating Expenses | $3,969,292 | $5,996,717 |
| Cash and Cash Equivalents (End of Period) | $3,468,338 | $8,217,115 |
| Stockholders' Equity | $3,867,855 | $8,756,680 |
| Net Cash Used in Operating Activities | $(4,161,425) | $(5,297,891) |
| Net Cash Provided by Financing Activities | $6,028,103 | $6,793,199 |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately 34% ($2.03 million) compared to Q1 2024. This was driven by a 22% reduction in R&D expenses (due to closing the Acclaim-2 trial and staff reductions) and a 47% reduction in G&A expenses (due to reduced travel, professional services, and headcount).
- Capital Raise: The company raised approximately $6.03 million in net proceeds during Q1 2025 through the sale of 13,278,666 shares of common stock under its At-The-Market (ATM) facility. This increased cash balances from $1.60 million at year-end 2024 to $3.47 million at March 31, 2025.
- Share Count: Outstanding common shares increased significantly from 10.86 million at December 31, 2024, to 24.15 million at March 31, 2025, primarily due to the ATM offering.
- Going Concern: The filing reiterates substantial doubt regarding the company's ability to continue as a going concern without additional financing, estimating current cash will fund operations only through the end of Q2 2025.
Outlook, Risks, and Management Commentary
- Clinical Progress:
- Acclaim-1 (NSCLC): Enrolling in Phase 2a expansion. Protocol amended in February 2025 to include patients progressing on Tagrisso or Tagrisso-containing regimens. Interim analysis expected in H1 2026.
- Acclaim-3 (SCLC): Enrolling in Phase 2 expansion. Interim analysis expected in H2 2025.
- Acclaim-2: Enrollment ceased in August 2024 due to resource prioritization.
- Strategic Restructuring: In February 2025, Genprex formed a wholly-owned subsidiary, Convergen Biotech, Inc., to house the diabetes program, aiming to separate development efforts from the oncology program.
- Liquidity Risk: The company has exhausted its capacity under the current ATM facility prospectus supplement as of the filing date. Additional capital is required to fund clinical trials and operations beyond Q2 2025.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, citing a lack of segregation of duties and insufficient depth of accounting personnel. Remediation efforts are underway.
- Nasdaq Compliance: The company reported regaining compliance with the minimum stockholders' equity requirement ($2.5 million) but remains non-compliant with the minimum bid price requirement ($1.00), with a deadline to regain compliance by August 6, 2025.
Investor Verification Checklist
- Verify the timeline and success of the interim analysis for the Acclaim-1 and Acclaim-3 trials, as these are critical milestones for future funding.
- Monitor the company's ability to secure additional financing before the end of Q2 2025, given the exhausted ATM capacity and stated cash runway.
- Review the progress of remediation plans for the identified material weaknesses in internal controls over financial reporting.
- Track the stock price to ensure compliance with Nasdaq's minimum bid price requirement by August 6, 2025, or watch for announcements regarding a potential reverse stock split.
- Assess the impact of the new subsidiary structure (Convergen Biotech) on the valuation and strategic focus of the diabetes versus oncology programs.